Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder

Therapeutics and Clinical Risk Management

Volumn 3, Issue 6, 2007, Pages 1003-1007

  Colombo, Renzo ^a   Naspro, Richard ^b   Bellinzoni, Piera ^b   Fabbri, Fabio ^b   Guazzoni, Giorgio ^b   Scattoni, Vincenzo ^a   Losa, Andrea ^b   Rigatti, Patrizio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Department of Urology ^*  (Italy)

Author keywords

Bladder cancer; Carcinoma in situ; Endoscopy; Fluorescence

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; BCG VACCINE; PHOTOCURE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTECTOMY; CYSTOSCOPY; DRUG SAFETY; FALSE POSITIVE RESULT; FLUORESCENCE ANALYSIS; FOLLOW UP; HUMAN; PHOTODYNAMICS; RELIABILITY; SURGICAL APPROACH; UNSPECIFIED SIDE EFFECT; URINE CYTOLOGY; WHITE LIGHT;

EID: 38049144233     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Colombo R. 2007. New procedures are bound to modify our attitude in facing urologic cancers in the near future: are we ready for a cost-effectiveness analysis? Eur Urol, 52:11-4.
2. Daniltchenko DI, Riedl CR, Sachs MD, et al. 2005. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol, 174:2129-33, discussion 2133.
3. Filbeck T, Pichlmeier U, Knuechel R, et al. 2002. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? Urology, 60:1025-8.
4. Filbeck T, Pichlmeier U, Knuechel R, et al. 2003. Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study. Urologe A, 42:1366-73.
5. Jocham D, Witjes F, Wagner S, et al. 2005. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol, 174:862-6.
6. Kiemeney LA, Witjes JA, Heijbroek RP, et al. 1994. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-Operative Urological Group. Br J Urol, 73:164-71.
7. Kriegmair M, Stepp H, Steinbach P, et al. 1995. Fluorescence cystoscopy following intravesical instillation of 5-aminolevulinic acid: a new procedure with high sensitivity for detection of hardly visible urothelial neoplasias. Urol Int, 55:190-6.
8. Kriegmair M, Zaak D, Rothenberger KH, et al. 2002. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol, 168:475-8.
9. Lamm DL. 1992. Carcinoma in situ. Urol Clin North Am, 19):499-508.
10. Loidl W, Schmidbauer J, Susani M, et al. 2005. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol, 47:323-6.
11. Grimbergen MC, van Swol CF, Jonges TG, et al. 2003. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol, 44:51-6.
12. Raitanen MP, Aine R, Rintala E, et al. FinnBladder Group. 2002 Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol, 41:284-9.
13. Riedl CR, Daniltchenko D, Koenig F, et al. 2001. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol, 165:1121-3.
14. Schmidbauer J, Witjes F, Schmeller N, et al. Hexvix PCB3O1/01 Study Group. 2004. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol, 171:135-8.
15. Sylvester RJ, van der Meijden A, Witjes JA, et al. 2005. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology, 66(Suppl 1):90-107
16. Witjes JA. 2004. Bladder carcinoma in situ in 2003: state of the art. Eur Urol, 45:142-6
17. Witjes JA, Moonen PM, van der Heijden AG. 2005. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. Eur Urol, 47:319-22.
18. Zaak D, Karl A, Knuchel R, et al. 2005. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int, 96:217-22.
19. Zaak D, Kriegmair M, Stepp H, et al. 2001. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology, 57:690-4.
20. Zaak D, Hungerhuber E, Schneede P, et al. 2002. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer, 95:1234-8.